November 2025

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ribociclib in N0 and N1 breast cancer.

During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant therapy choices in breast cancer.

During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.

During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.